VIRX - Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference
PR Newswire
SAN DIEGO , March 3, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10 , 2021. A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021 . Viracta's management team will also be available for one-on-one investor meetings at the conference.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com .
Investor Relations Contact: |
Company Contact: |
|
|
Joyce Allaire |
Dan Chevallard |
LifeSci Advisors |
Chief Financial Officer |
(212) 915-2569 |
(858) 771-4193 |
SOURCE Viracta
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.